Seoul, Korea
Samsung is planning to build a biologics manufacturing facility near Seoul in Korea. The project reflects a $266 million partnership with Quintiles to produce biosimilar versions of successful pharmaceutical treatments. Production is expected to begin in the new facility in late 2012.
